1 March 2016 - This assessement was about patients with highly active relapsing-remitting multiple sclerosis, on a full and adequate course who have not responded to least one other disease therapy. For this assessment, an additional benefit of fingolimod versus the appropriate comparator therapies according is not occupied.

For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/fingolimod-bei-multipler-sklerose-kein-anhaltspunkt-fur-zusatznutzen-im-neuen-anwendungsgebiet.7194.html?&et_cid=4&et_lid=%25208